Ethyl Isothiocyanate as a Novel Antifungal Agent Against Candida albicans.
Journal
Current microbiology
ISSN: 1432-0991
Titre abrégé: Curr Microbiol
Pays: United States
ID NLM: 7808448
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
received:
09
08
2023
accepted:
25
10
2023
medline:
7
12
2023
pubmed:
5
12
2023
entrez:
5
12
2023
Statut:
epublish
Résumé
In the recent years, occurrence of candidiasis has increased drastically which leads to significant mortality and morbidity mainly in immune compromised patients. Glucosinolate (GLS) derivatives are reported to have antifungal activities. Ethyl isothiocyanate (EITC) and its antifungal activity and mechanism of action is still unclear against Candida albicans. The present work was designed to get a mechanistic insight in to the anti-Candida efficacy of EITC through in vitro and in vivo studies. EITC inhibited C. albicans planktonic growth at 0.5 mg/ml and virulence factors like yeast to hyphal form morphogenesis (0.0312 mg/ml), adhesion to polystyrene surface (0.0312 mg/ml) and biofilm formation (developing biofilm at 2 mg/ml and mature biofilm at 0.5 mg/ml) effectively. EITC blocked ergosterol biosynthesis and arrested C. albicans cells at S-phase. EITC caused ROS-dependent cellular death and nuclear or DNA fragmentation. EITC at 0.0312 mg/ml concentration regulated the expression of genes involved in the signal transduction pathway and inhibited yeast to hyphal form morphogenesis by upregulating TUP1, MIG1, and NRG1 by 3.10, 5.84 and 2.64-fold, respectively and downregulating PDE2 and CEK1 genes by 15.38 and 2.10-fold, respectively. EITC has showed haemolytic activity at 0.5 mg/ml concentration. In vivo study in silk worm model showed that EITC has toxicity to C. albicans at 0.5 mg/ml concentration. Thus, from present study we conclude that EITC has antifungal activity and to reduce its MIC and toxicity, combination study with other antifungal drugs need to be done. EITC and its combinations might be used as alternative therapeutics for the prevention and treatment of C. albicans infections.
Identifiants
pubmed: 38051343
doi: 10.1007/s00284-023-03542-3
pii: 10.1007/s00284-023-03542-3
doi:
Substances chimiques
Antifungal Agents
0
ethyl isothiocyanate
3284MJ2T8P
Isothiocyanates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : D.Y. Patil Education Society Institution Deemed to be University Kolhapur
ID : DYPES/DU/R&D/2021/273
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Mayer FL, Wilson D, Hube B (2013) Candida albicans pathogenicity mechanisms. Virulence 4:119–128
doi: 10.4161/viru.22913
pubmed: 23302789
pmcid: 3654610
Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I (2021) Candida albicans-the virulence factors and clinical manifestations of infection. J Fungi 7:1–19
doi: 10.3390/jof7020079
Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17:255–267
doi: 10.1128/CMR.17.2.255-267.2004
pubmed: 15084500
pmcid: 387407
Privett BJ, Nutz ST, Schoenfisch MH (2010) Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation. Biofouling 26:973–983
doi: 10.1080/08927014.2010.534552
pubmed: 21082455
pmcid: 3566635
Campbell BC, Chan KL, Kim JH (2012) Chemosensitization as a means to augment commercial antifungal agents. Front Microbiol 3:1–20
doi: 10.3389/fmicb.2012.00079
Scorzoni L, de Paula e Silva ACA, Marcos CM, Assato PA, de Melo WCMA, de Oliveira HC, Costa-Orlandi CB, Mendes-Giannini MJS, Fusco-Almeida AM (2017) Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol 8:1–23
doi: 10.3389/fmicb.2017.00036
Van Daele R, Spriet I, Wauters J, Maertens J, Mercier T, Van Hecke S, Brüggemann R (2019) Antifungal drugs: what brings the future? Med Mycol 57:S328–S343
doi: 10.1093/mmy/myz012
pubmed: 31292663
Thakre A, Zore G, Kodgire S et al (2017) OUP accepted manuscript. Med Mycol 56:565–578
Singla RK, Dubey AK (2019) Molecules and metabolites from natural products as inhibitors of biofilm in Candida spp. pathogens. Curr Top Med Chem 19:2567–2578
doi: 10.2174/1568026619666191025154834
pubmed: 31654510
pmcid: 7403689
Le TN, Chiu C, Hsieh P (2020) And microgreens: an updated overview from a nutraceutical perspective. Plant Sci Today 9:1–23
Kurt Ş, Güneş U, Soylu EM (2011) In vitro and in vivo antifungal activity of synthetic pure isothiocyanates against Sclerotinia sclerotiorum. Pest Manag Sci 67:869–875
doi: 10.1002/ps.2126
pubmed: 21370393
Smolinska U, Morra MJ, Knudsen GR, James RL (2003) Isothiocyanates produced by Brassicaceae species as inhibitors of Fusarium oxysporum. Plant Dis 87:407–412
doi: 10.1094/PDIS.2003.87.4.407
pubmed: 30831837
Plaszkó T, Szűcs Z, Vasas G, Gonda S (2021) Effects of glucosinolate-derived isothiocyanates on fungi: A comprehensive review on direct effects, mechanisms, structure-activity relationship data and possible agricultural applications. J Fungi 7:1–38
doi: 10.3390/jof7070539
Pereira C, Calado AM, Sampaio AC (2020) The effect of benzyl isothiocyanate on Candida albicans growth, cell size, morphogenesis, and ultrastructure. World J Microbiol Biotechnol 36:1–12
doi: 10.1007/s11274-020-02929-9
Raut JS, Shinde RB, Chauhan NM, Mohan Karuppayil S (2013) Terpenoids of plant origin inhibit morphogenesis, adhesion, and biofilm formation by Candida albicans. Biofouling 29:87–96
doi: 10.1080/08927014.2012.749398
pubmed: 23216018
Jadhav A, Mortale S, Halbandge S, Jangid P, Patil R, Gade W, Kharat K, Karuppayil SM (2017) The dietary food components capric acid and caprylic acid inhibit virulence factors in Candida albicans through multitargeting. J Med Food 20:1083–1090
doi: 10.1089/jmf.2017.3971
pubmed: 28922057
Shinde RB, Raut JS, Karuppayil MS (2012) Biofilm formation by Candida albicans on various prosthetic materials and its fluconazole sensitivity: A kinetic study. Mycoscience 53:220–226
doi: 10.1007/S10267-011-0155-Y
Raut JS, Bansode BS, Jadhav AK, Karuppayil SM (2017) Activity of allyl isothiocyanate and its synergy with fluconazole against Candida albicans biofilms. J Microbiol Biotechnol 27:685–693
doi: 10.4014/jmb.1607.07072
pubmed: 28138121
Priya A, Pandian SK (2020) Piperine impedes biofilm formation and hyphal morphogenesis of Candida albicans. Front Microbiol 11:1–18
doi: 10.3389/fmicb.2020.00756
Radhakrishnan VS, Dwivedi SP, Siddiqui MH, Prasad T (2018) In vitro studies on oxidative stress-independent, ag nanoparticles-induced cell toxicity of Candida albicans, an opportunistic pathogen. Int J Nanomedicine 13:91–96
doi: 10.2147/IJN.S125010
pubmed: 29593404
pmcid: 5863646
Ahamad I, Bano F, Anwer R, Srivastava P, Kumar R, Fatma T (2022) Antibiofilm activities of biogenic silver nanoparticles against Candida albicans. Front Microbiol 12:1–13
doi: 10.3389/fmicb.2021.741493
Zore GB, Thakre AD, Jadhav S, Karuppayil SM (2011) Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle. Phytomedicine 18:1181–1190
doi: 10.1016/j.phymed.2011.03.008
pubmed: 21596542
Ahmad A, Khan A, Manzoor N, Khan LA (2010) Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida. Microb Pathog 48:35–41
doi: 10.1016/j.micpath.2009.10.001
pubmed: 19835945
Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL (2017) Targeting Candida albicans filamentation for antifungal drug development. Virulence 8:150–158
doi: 10.1080/21505594.2016.1197444
pubmed: 27268130
Hasegawa S, Yamada Y, Iwanami N, Nakayama Y, Nakayama H, Iwatani S, Oura T, Kajiwara S (2019) Identification and functional characterization of Candida albicans mannose–ethanolamine phosphotransferase (Mcd4p). Curr Genet 65:1251–1261
doi: 10.1007/s00294-019-00987-7
pubmed: 31073667
Choi H, Lee DG (2015) Lycopene induces apoptosis in Candida albicans through reactive oxygen species production and mitochondrial dysfunction. Biochimie 115:108–115
doi: 10.1016/j.biochi.2015.05.009
pubmed: 26005097
Rajput SB, Mohan Karuppayil S (2013) Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans. Springerplus 2:1–6
doi: 10.1186/2193-1801-2-26
Zorić N, Kosalec I, Tomić S, Bobnjarić I, Jug M, Vlainić T, Vlainić J (2017) Membrane of Candida albicans as a target of berberine. BMC Complement Altern Med 17:1–10
doi: 10.1186/s12906-017-1773-5
Chang W, Li Y, Zhang L, Cheng A, Lou H (2012) Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PLoS ONE 7:1–10
Zou L, Mei Z, Guan T, Zhang B, Deng Q (2021) Underlying mechanisms of the effect of minocycline against Candida albicans biofilms. Exp Ther Med 21:1–9
doi: 10.3892/etm.2021.9857
Park YK, Shin J, Lee H-Y, Kim HD, Kim J (2021) Inhibition of Ras1-MAPK pathways for hypha formation by novel drug candidates in. BioRxtv 1:1–44
Cavalheiro M, Teixeira MC (2018) Candida biofilms: threats, challenges, and promising strategies. Front Med 5:1–15
doi: 10.3389/fmed.2018.00028
Garip Z, Harran FT (2021) Silkworm in pharmacology and toxicology. Int J Vet Anim Res 4:34–38